Coherus Biosciences, Inc. (CHRS)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
28.79-2.13 (-6.89%)
At close: 4:00 PM EDT

28.79 0.00 (0.00%)
After hours: 4:58 PM EDT

People also watch:
CACHPLCECBKSMRTBEBE
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open31.08
Prev Close30.92
Bid18.00 x 100
Ask30.95 x 100
Day's Range28.75 - 31.16
52wk Range12.04 - 31.98
1y Target EstN/A
Market Cap1.25B
P/E Ratio (ttm)-4.37
BetaN/A
Volume362,840
Avg Vol (3m)396,356
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Barrons.com8 hours ago

    [$$] Coherus, Momenta Set for Different Outcomes

    Maxim Group A seemingly benign, and to us an expected event from Shire, could translate into two very different outcomes for Coherus BioSciences and Momenta Pharmaceuticals. Both Coherus and Momenta announced that Shire (SHPG) has returned rights to each of their anti-TNF biosimilars: Coherus’ CHS-0214 (Enbrel) and Momenta’s M923 (Humira). The announcement was not a complete surprise as Shire had openly discussed the potential of not developing biosimilars that came on board as a result of the acquisition of Baxalta.

  • GlobeNewswire2 days ago

    Coherus BioSciences Regains Development and Commercial Rights to CHS-0214 From Shire

    REDWOOD CITY, Calif., Sept. 27, 2016-- Coherus BioSciences, Inc. today announced that it has regained from Shire plc all development and commercial rights previously licensed for CHS-0214 etanercept, a ...

  • 3 Biotechs With Potential Big-Time Upside
    Motley Fool2 days ago

    3 Biotechs With Potential Big-Time Upside

    These three high-risk/high-reward biotechs have drugs in late-stage trials and key catalysts just around the corner.